

CORPORATE ACTIONS

Stocks	Ex-Date	Purpose	Amount (Rs)	Record Date
3I INFOTECH LTD.	30 Aug 2021	Reduction of Capital	-	31 Aug 2021
Bella Casa Fashion & Retail Ltd	30 Aug 2021	Final Dividend	0.35	-
BENGAL & ASSAM COMPANY LTD.	30 Aug 2021	Dividend	7.50	-
GANDHI SPECIAL TUBES LTD.	30 Aug 2021	Buy Back of Shares	-	31 Aug 2021
HLE Glascoat Ltd	30 Aug 2021	Dividend	4.00	-
INDIA MOTOR PARTS & ACCESSORIES LTD.	30 Aug 2021	Dividend	10.00	-
JENBURKT PHARMACEUTICALS LTD.	30 Aug 2021	Dividend	10.20	-
JK Agri Genetics Ltd	30 Aug 2021	Dividend	1.50	-
Kama Holdings Limited	30 Aug 2021	Interim Dividend	51.00	31 Aug 2021
Kanco Tea & Industries Ltd	30 Aug 2021	Dividend	1.00	-
KITEX GARMENTS LTD.	30 Aug 2021	Final Dividend	1.50	-
NALIN LEASE FINANCE LTD.	30 Aug 2021	Dividend	0.50	-
PRIMA PLASTICS LTD.	30 Aug 2021	Final Dividend	1.50	-
Smart Finsec Ltd	30 Aug 2021	Stock Split From Rs.10/- to Rs.1/-	-	31 Aug 2021
SOUTH INDIA PAPER MILLS LTD.	30 Aug 2021	Dividend	1.00	-
UMANG DAIRIES LTD.	30 Aug 2021	Dividend	0.50	-
Advanced Enzyme Technologies Ltd	31 Aug 2021	Final Dividend	0.90	01 Sep 2021
ASHOK LEYLAND LTD.	31 Aug 2021	Final Dividend	0.60	-
CENTURY PLYBOARDS (I) LTD.	31 Aug 2021	Final Dividend	1.00	-
Galaxy Surfactants Ltd	31 Aug 2021	Final Dividend	4.00	01 Sep 2021
INDIA CEMENTS LTD.	31 Aug 2021	Dividend	1.00	-
POWER FINANCE CORPORATION LTD.	31 Aug 2021	Interim Dividend	2.25	01 Sep 2021
PODDAR PIGMENTS LTD.	31 Aug 2021	Final Dividend	2.50	-
PREMCO GLOBAL LTD.	31 Aug 2021	Interim Dividend	3.00	01 Sep 2021
ROSSELL INDIA LTD.	31 Aug 2021	Final Dividend	0.30	-
BANNARI AMMAN SUGARS LTD.	01 Sep 2021	Dividend	10.00	-
GeeCee Ventures Limited	01 Sep 2021	Dividend	1.90	02 Sep 2021
J.B.CHEMICALS & PHARMACEUTICALS LTD.	01 Sep 2021	Final Dividend	8.00	-
JOST'S ENGINEERING CO.LTD.	01 Sep 2021	Final Dividend	3.00	-
K.P.R. Mill Limited	01 Sep 2021	Final Dividend	0.75	-
LAMBODHARA TEXTILES LTD.	01 Sep 2021	Dividend	1.00	-
L.G.BALAKRISHNAN & BROS.LTD.	01 Sep 2021	Dividend	10.00	-
Mallcom (India) Ltd	01 Sep 2021	Final Dividend	3.00	-
TPL PLASTECH LTD.	01 Sep 2021	Final Dividend	3.50	-
ARCHIT ORGANOSYS LTD.	02 Sep 2021	Dividend	0.50	-
ASHIANA HOUSING LTD.	02 Sep 2021	Final Dividend	0.40	-
COAL INDIA LTD.	02 Sep 2021	Final Dividend	3.50	03 Sep 2021
Garden Reach Shipbuilders & Engineers Ltd	02 Sep 2021	Final Dividend	1.15	-
Jtekt India Ltd	02 Sep 2021	Final Dividend	0.15	-
KOVAI MEDICAL CENTER & HOSPITAL LTD.	02 Sep 2021	Final Dividend	3.00	-
MANALI PETROCHEMICAL LTD.	02 Sep 2021	Dividend	1.50	-
PNB GILTS LTD.	02 Sep 2021	Final Dividend	3.00	04 Sep 2021
SURYA ROSHNI LTD.	02 Sep 2021	Final Dividend	1.50	03 Sep 2021
TAMILNADU PETROPRODUCTS LTD.	02 Sep 2021	Final Dividend	2.50	-
TRANSFORMERS AND RECTIFIERS (INDIA) LTD.	02 Sep 2021	Final Dividend	0.10	-
VOITH PAPER FABRICS INDIA LTD.	02 Sep 2021	Final Dividend	5.00	-
VARDHMAN SPECIAL STEELS LTD.	02 Sep 2021	Dividend	1.50	-
ZEE ENTERTAINMENT ENTERPRISES LTD.	02 Sep 2021	Final Dividend	2.50	03 Sep 2021
ALLIED DIGITAL SERVICES LTD.	03 Sep 2021	Final Dividend	0.75	06 Sep 2021
BANCO PRODUCTS (INDIA) LTD.	03 Sep 2021	Dividend	2.00	-
BOMBAY BURMAH TRADING CORP. LTD.	03 Sep 2021	Dividend	1.20	-
MOTHERSON SUMI SYSTEMS LTD.	03 Sep 2021	Final Dividend	1.50	-
Nakoda Group of Industries Ltd	03 Sep 2021	Final Dividend	0.10	06 Sep 2021
Sarthak Metals Ltd	03 Sep 2021	Final Dividend	1.00	-
S.P. Apparels Ltd	03 Sep 2021	Final Dividend	2.25	-
VICTORIA MILLS LTD.	03 Sep 2021	Final Dividend	50.00	-
YUKEN INDIA LTD.	03 Sep 2021	Final Dividend	0.60	-

OFFER TO BUY

Company name	Start Date	Close Date	Offer Price (Rs.)	Proposed Acquisition (No. of shares)	CMP (Rs.)
RICHFIELD FINANCIAL SERVICES LTD	02-Sep-21	16-Sep-21	23.10	9,75,026	-

Weekly View: Nifty, Bank Nifty:

Indices	CMP	Support	Resistance	50 DMA	200 DMA	Range	Preferred Trade
NIFTY	16705	16491	17001	16016	14829	16501-17001	Buy at CMP. Targets at 17001 /17251. Stop at 16488.
BANK NIFTY	35628	34115	37001	35276	33404	34555-37001	Buy at CMP. Targets at 36001 /36651/37001. Stop at 33921.

Medium Term Pick:

Stocks	CMP	Support	Resistance	50 DMA	200 DMA	Bias	Preferred Trade
CIPLA	924	867	1001	939	864	Positive	CIPLA is a leading global pharmaceutical company with presence in 80+ countries and large presence in India, South Africa and the U.S. Cipla provides over 1,500 products across various therapeutic categories with strong positions in respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS as well as other key therapeutic segments. The positive catalysts are a robust Q1FY22 performance, better US outlook for F23, cost control, and productivity improvement. A potential entrance exists at CMP, and on dips between 875-887 zone, targeting 1001/1057 mark and then aggressive targets at 1101 mark. Holding Period: 3-5 Months+. Stop at 867.

Incorporated in 1935 by Dr K.A Hamied, **Cipla** now commands a market cap of a market cap of Rs 74,500 Crore and is a leading global pharmaceutical company with presence in 80+ countries and large presence in India, South Africa and the U.S.

Cipla has 46 manufacturing facilities located at various countries for manufacturing API and formulations and with 25000 plus employees. Cipla provides over 1,500 products across various therapeutic categories with strong positions in respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS as well as other key therapeutic segments. In line with national and international standards, Cipla's state-of-the-art manufacturing facilities are cGMP compliant. Many a dosages and APIs manufactured at these facilities to be approved by major international regulatory agencies including the US FDA, MHRA (UK), TGA (Australia), Federal Ministry of Health Germany, SAPHRA (South Africa), the Department of Health (Canada), INVIMA (Columbia) ANVISA (Brazil), the Danish Medical Agency, WHO and Ministry of Health of various countries.

The outlook continues to be promising outlook amidst positive catalysts like:

- # Base business continues to strengthen and sales momentum to continue in F22 and Indian market to return to 10-12% growth excluding COVID portfolio.
- # Leadership in complex respiratory products and most importantly, the respiratory monetization in the US is gaining momentum.
- # Robust COVID portfolio along with a strong chronic portfolio pipeline comprising of 165 approved ANDAs, 19 tentatively approved and 64 awaiting US FDA approval taking cumulative total to 248 ANDAs with USFDA as of Mar 2021.
- # Rich US pipeline: New launches like gAdvair, gRevlimid, gAbroxane, gBrovana and arformoterol will drive growth in the US markets in Fy23.
- # Management expects FY22 EBITDA margin at ~22.5% on backdrop of new launches in the US and margins holding at current levels.
- # Digital initiatives: To boost its digital footprint, a strategic investment of Rs. 40 crore was made in a rapidly growing health-tech firm.
- # The balance sheet is getting healthy as has Rs29bn net cash, which it plans to utilize for strategic initiatives and dividends.

A potential entrance exists at CMP, and on dips between 875-887 zone, targeting 1001/1057 mark and then aggressive targets at 1101 mark. Holding Period: 3-5 Months+. Stop at 867.

Daily Chart of CIPLA:

